Skip to main content
PMC home page
Gut logoLink to Gut
. 1990 Jan;31(1):21–25. doi: 10.1136/gut.31.1.21

Effects of cisapride on parameters of oesophageal motility and on the prolonged intraoesophageal pH test in infants with gastro-oesophageal reflux disease.

S Cucchiara 1, A Staiano 1, A Boccieri 1, M De Stefano 1, C Capozzi 1, G Manzi 1, F Camerlingo 1, F M Paone 1
PMCID: PMC1378335  PMID: 2180792

Abstract

The effect of cisapride, a new gastrointestinal prokinetic drug, on oesophageal motility and acid reflux was studied in 14 children with gastro-oesophageal reflux disease, receiving either placebo or cisapride 0.15 mg/kg intravenously. Cisapride significantly (p less than 0.01) increased the lower oesophageal sphincter pressure (+124%), the amplitude (+84%) and duration (+24%) of oesophageal peristaltic waves, whereas the placebo treatment did not produce any changes. Subsequently, all 14 children underwent 24 hour oesophageal pH-monitoring before and after four weeks of treatment with oral cisapride 0.2 mg/kg tid given in addition to postural therapy and thickened feedings. The 24 hour intraoesophageal pH recordings and symptomatic scores were compared with those of 10 control patients treated only by postural therapy and thickened feedings. When compared with baseline pH data, cisapride significantly reduced the oesophageal acid exposure time, the mean duration of each reflux episode, the duration of the longest reflux episode and the number of long lasting reflux episodes; the number of reflux episodes was not influenced. The effect of cisapride was marked and consistent during fasting and sleep periods. Oesophageal acid exposure was reduced more significantly in patients given cisapride (-61%) than in controls (-24%; p less than 0.001). Symptom improvement was greater after four weeks of cisapride treatment (score reduction: 61%) than after postural and dietary therapy alone (score reduction: 42%; p less than 0.01). No adverse effects occurred. These findings suggest that cisapride is a valuable drug in the management of gastro-oesophageal reflux disease in children.

Full text

PDF
21

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atkinson M. Monitoring oesophageal pH. Gut. 1987 May;28(5):509–514. doi: 10.1136/gut.28.5.509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Camilleri M., Brown M. L., Malagelada J. R. Impaired transit of chyme in chronic intestinal pseudoobstruction. Correction by cisapride. Gastroenterology. 1986 Sep;91(3):619–626. doi: 10.1016/0016-5085(86)90631-1. [DOI] [PubMed] [Google Scholar]
  3. Castell D. O. Medical therapy for reflux esophagitis: 1986 and beyond. Ann Intern Med. 1986 Jan;104(1):112–114. doi: 10.7326/0003-4819-104-1-112. [DOI] [PubMed] [Google Scholar]
  4. Crist J., Gidda J. S., Goyal R. K. Intramural mechanism of esophageal peristalsis: roles of cholinergic and noncholinergic nerves. Proc Natl Acad Sci U S A. 1984 Jun;81(11):3595–3599. doi: 10.1073/pnas.81.11.3595. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cucchiara S., Staiano A., Capozzi C., Di Lorenzo C., Boccieri A., Auricchio S. Cisapride for gastro-oesophageal reflux and peptic oesophagitis. Arch Dis Child. 1987 May;62(5):454–457. doi: 10.1136/adc.62.5.454. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dent J., Holloway R. H., Toouli J., Dodds W. J. Mechanisms of lower oesophageal sphincter incompetence in patients with symptomatic gastrooesophageal reflux. Gut. 1988 Aug;29(8):1020–1028. doi: 10.1136/gut.29.8.1020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dent J. Recent views on the pathogenesis of gastro-oesophageal reflux disease. Baillieres Clin Gastroenterol. 1987 Oct;1(4):727–745. doi: 10.1016/0950-3528(87)90016-9. [DOI] [PubMed] [Google Scholar]
  8. Forbes D., Hodgson M., Hill R. The effects of gaviscon and metoclopramide in gastroesophageal reflux in children. J Pediatr Gastroenterol Nutr. 1986 Jul-Aug;5(4):556–559. doi: 10.1097/00005176-198607000-00008. [DOI] [PubMed] [Google Scholar]
  9. Franckx J., Noel P. Acute extrapyramidal dysfunction after domperidone administration. Report of a case. Helv Paediatr Acta. 1984 Aug;39(3):285–288. [PubMed] [Google Scholar]
  10. Grill B. B., Hillemeier A. C., Semeraro L. A., McCallum R. W., Gryboski J. D. Effects of domperidone therapy on symptoms and upper gastrointestinal motility in infants with gastroesophageal reflux. J Pediatr. 1985 Feb;106(2):311–316. doi: 10.1016/s0022-3476(85)80315-2. [DOI] [PubMed] [Google Scholar]
  11. Helm J. F., Dodds W. J., Pelc L. R., Palmer D. W., Hogan W. J., Teeter B. C. Effect of esophageal emptying and saliva on clearance of acid from the esophagus. N Engl J Med. 1984 Feb 2;310(5):284–288. doi: 10.1056/NEJM198402023100503. [DOI] [PubMed] [Google Scholar]
  12. Herbst J. J. Gastroesophageal reflux. J Pediatr. 1981 Jun;98(6):859–870. doi: 10.1016/s0022-3476(81)80576-8. [DOI] [PubMed] [Google Scholar]
  13. Holloway R. H., Hongo M., Berger K., McCallum R. W. Gastric distention: a mechanism for postprandial gastroesophageal reflux. Gastroenterology. 1985 Oct;89(4):779–784. doi: 10.1016/0016-5085(85)90572-4. [DOI] [PubMed] [Google Scholar]
  14. Hyams J. S., Leichtner A. M., Zamett L. O., Walters J. K. Effect of metoclopramide on prolonged intraesophageal pH testing in infants with gastroesophageal reflux. J Pediatr Gastroenterol Nutr. 1986 Sep-Oct;5(5):716–720. doi: 10.1097/00005176-198609000-00008. [DOI] [PubMed] [Google Scholar]
  15. Hyman P. E., McDiarmid S. V., Napolitano J., Abrams C. E., Tomomasa T. Antroduodenal motility in children with chronic intestinal pseudo-obstruction. J Pediatr. 1988 Jun;112(6):899–905. doi: 10.1016/s0022-3476(88)80211-7. [DOI] [PubMed] [Google Scholar]
  16. Kahrilas P. J., Dodds W. J., Hogan W. J. Effect of peristaltic dysfunction on esophageal volume clearance. Gastroenterology. 1988 Jan;94(1):73–80. doi: 10.1016/0016-5085(88)90612-9. [DOI] [PubMed] [Google Scholar]
  17. Kahrilas P. J., Dodds W. J., Hogan W. J., Kern M., Arndorfer R. C., Reece A. Esophageal peristaltic dysfunction in peptic esophagitis. Gastroenterology. 1986 Oct;91(4):897–904. doi: 10.1016/0016-5085(86)90692-x. [DOI] [PubMed] [Google Scholar]
  18. Orenstein S. R., Lofton S. W., Orenstein D. M. Bethanechol for pediatric gastroesophageal reflux: a prospective, blind, controlled study. J Pediatr Gastroenterol Nutr. 1986 Jul-Aug;5(4):549–555. doi: 10.1097/00005176-198607000-00007. [DOI] [PubMed] [Google Scholar]
  19. Richter J. E., Castell D. O. Drugs, foods, and other substances in the cause and treatment of reflux esophagitis. Med Clin North Am. 1981 Nov;65(6):1223–1234. doi: 10.1016/s0025-7125(16)31470-5. [DOI] [PubMed] [Google Scholar]
  20. Saye Z. N., Forget P. P., Geubelle F. Effect of cisapride on gastroesophageal reflux in children with chronic bronchopulmonary disease: a double-blind cross-over pH-monitoring study. Pediatr Pulmonol. 1987 Jan-Feb;3(1):8–12. doi: 10.1002/ppul.1950030105. [DOI] [PubMed] [Google Scholar]
  21. Schuurkes J. A., Van Nueten J. M., Van Daele P. G., Reyntjens A. J., Janssen P. A. Motor-stimulating properties of cisapride on isolated gastrointestinal preparations of the guinea pig. J Pharmacol Exp Ther. 1985 Sep;234(3):775–783. [PubMed] [Google Scholar]
  22. Sondheimer J. M., Mintz H. L., Michaels M. Bethanechol treatment of gastroesophageal reflux in infants: effect on continuous esophageal pH records. J Pediatr. 1984 Jan;104(1):128–131. doi: 10.1016/s0022-3476(84)80609-5. [DOI] [PubMed] [Google Scholar]
  23. Strickland A. D., Chang J. H. Results of treatment of gastroesophageal reflux with bethanechol. J Pediatr. 1983 Aug;103(2):311–315. doi: 10.1016/s0022-3476(83)80375-8. [DOI] [PubMed] [Google Scholar]
  24. Tytgat G. N., Nio C. Y. The medical therapy of reflux oesophagitis. Baillieres Clin Gastroenterol. 1987 Oct;1(4):791–807. doi: 10.1016/0950-3528(87)90019-4. [DOI] [PubMed] [Google Scholar]
  25. Weihrauch T. R. Gastro-oesophageal reflux--pathogenesis and clinical implications. Eur J Pediatr. 1985 Sep;144(3):215–218. doi: 10.1007/BF00451943. [DOI] [PubMed] [Google Scholar]
  26. van der Steen M., Du Caju M. V., Van Acker K. J. Gynecomastia in a male infant given domperidone. Lancet. 1982 Oct 16;2(8303):884–885. doi: 10.1016/s0140-6736(82)90857-1. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES